Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3471851 in Participants With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a confirmed diagnosis of psoriasis for at least 6 months~* Have active psoriasis plaques according to study- specific criteria~* Be willing and able to undergo skin biopsies~Exclusion Criteria:~* Have received certain topical medications for psoriasis within 14 days prior to baseline~* Have received certain systemic medications for psoriasis within 4 weeks prior to baseline~* Have received LY3471851 previously

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered subcutaneously (SC) every 2 weeks for a period of 12 weeks.
- Cohort 1 - 10 (Microgram Per Kilogram) μg/kg LY3471851 (Type: EXPERIMENTAL): Participants received 10 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.
- Cohort 2 - 24 μg/kg LY3471851 (Type: EXPERIMENTAL): Participants received 24 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).